59 related articles for article (PubMed ID: 27139836)
21. Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template.
Yamazoe Y; Tohkin M
Drug Metab Pharmacokinet; 2021 Jun; 38():100357. PubMed ID: 33866277
[TBL] [Abstract][Full Text] [Related]
22. Identification of a null allele of cytochrome P450 3A7: CYP3A7 polymorphism in a Korean population.
Lee SS; Jung HJ; Park JS; Cha IJ; Cho DY; Shin JG
Mol Biol Rep; 2010 Jan; 37(1):213-7. PubMed ID: 19585271
[TBL] [Abstract][Full Text] [Related]
23. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy.
Apellániz-Ruiz M; Lee MY; Sánchez-Barroso L; Gutiérrez-Gutiérrez G; Calvo I; García-Estévez L; Sereno M; García-Donás J; Castelo B; Guerra E; Leandro-García LJ; Cascón A; Johansson I; Robledo M; Ingelman-Sundberg M; Rodríguez-Antona C
Clin Cancer Res; 2015 Jan; 21(2):322-8. PubMed ID: 25398452
[TBL] [Abstract][Full Text] [Related]
24. Functional assessment of
Fang P; Tang PF; Xu RA; Zheng X; Wen J; Bao SS; Cai JP; Hu GX
Drug Des Devel Ther; 2017; 11():3503-3510. PubMed ID: 29263648
[TBL] [Abstract][Full Text] [Related]
25. The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
Perera MA
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):17-28. PubMed ID: 19968573
[TBL] [Abstract][Full Text] [Related]
26. High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme.
Apellániz-Ruiz M; Inglada-Pérez L; Naranjo ME; Sánchez L; Mancikova V; Currás-Freixes M; de Cubas AA; Comino-Méndez I; Triki S; Rebai A; Rasool M; Moya G; Grazina M; Opocher G; Cascón A; Taboada-Echalar P; Ingelman-Sundberg M; Carracedo A; Robledo M; Llerena A; Rodríguez-Antona C
Pharmacogenomics J; 2015 Jun; 15(3):288-92. PubMed ID: 25348618
[TBL] [Abstract][Full Text] [Related]
27. CYP3A variation and the evolution of salt-sensitivity variants.
Thompson EE; Kuttab-Boulos H; Witonsky D; Yang L; Roe BA; Di Rienzo A
Am J Hum Genet; 2004 Dec; 75(6):1059-69. PubMed ID: 15492926
[TBL] [Abstract][Full Text] [Related]
28. Genetic analysis of drug metabolizing phase-I enzymes CYP3A4 in Tibetan populations.
Liu L; Chang Y; Du S; Shi X; Yang H; Kang L; Jin T; Yuan D; He Y
J Genet; 2017 Jun; 96(2):219-225. PubMed ID: 28674221
[TBL] [Abstract][Full Text] [Related]
29. Overlapping between CYP3A4 and CYP3A7 expression in the fetal human liver during development.
Fanni D; Fanos V; Ambu R; Lai F; Gerosa C; Pampaloni P; Van Eyken P; Senes G; Castagnola M; Faa G
J Matern Fetal Neonatal Med; 2015 Jul; 28(11):1291-1295. PubMed ID: 25208228
[TBL] [Abstract][Full Text] [Related]
30. Cis-acting regulatory elements regulating CYP3A4 transcription in human liver.
Collins JM; Wang D
Pharmacogenet Genomics; 2020 Jul; 30(5):107-116. PubMed ID: 32301865
[TBL] [Abstract][Full Text] [Related]
31. Cytochrome and sulfotransferase gene variation in north African populations.
Fernández-Santander A; Novillo A; Gaibar M; Romero-Lorca A; Moral P; Sánchez-Cuenca D; Amir N; Chaabani H; Harich N; Esteban ME
Pharmacogenomics; 2016 Aug; 17(13):1415-23. PubMed ID: 27471773
[TBL] [Abstract][Full Text] [Related]
32. CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme.
Browning SL; Tarekegn A; Bekele E; Bradman N; Thomas MG
Pharmacogenet Genomics; 2010 Nov; 20(11):647-64. PubMed ID: 20881513
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the genetic variation present in CYP3A4 in three South African populations.
Drögemöller B; Plummer M; Korkie L; Agenbag G; Dunaiski A; Niehaus D; Koen L; Gebhardt S; Schneider N; Olckers A; Wright G; Warnich L
Front Genet; 2013; 4():17. PubMed ID: 23423246
[TBL] [Abstract][Full Text] [Related]
34. Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.
Li H; Lampe JN
Arch Biochem Biophys; 2019 Sep; 673():108078. PubMed ID: 31445893
[TBL] [Abstract][Full Text] [Related]
35. Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform.
Kabir M; Padilha EC; Shah P; Huang R; Sakamuru S; Gonzalez E; Ye L; Hu X; Henderson MJ; Xia M; Xu X
Front Pharmacol; 2022; 13():899536. PubMed ID: 35847040
[TBL] [Abstract][Full Text] [Related]
36. Consequences of cis-regulatory sequence variation.
Fudge JB
Nat Biotechnol; 2023 Feb; 41(2):194. PubMed ID: 36792710
[No Abstract] [Full Text] [Related]
37. RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Amirimani B; Walker AH; Weber BL; Rebbeck TR
J Natl Cancer Inst; 1999 Sep; 91(18):1588-90. PubMed ID: 10491443
[No Abstract] [Full Text] [Related]
38. Evidence of the interplay of genetics and culture in Ethiopia.
López S; Tarekegn A; Band G; van Dorp L; Bird N; Morris S; Oljira T; Mekonnen E; Bekele E; Blench R; Thomas MG; Bradman N; Hellenthal G
Nat Commun; 2021 Jun; 12(1):3581. PubMed ID: 34117245
[TBL] [Abstract][Full Text] [Related]
39. Contrasting exome constancy and regulatory region variation in the gene encoding CYP3A4: an examination of the extent and potential implications.
Creemer OJ; Ansari-Pour N; Ekong R; Tarekegn A; Plaster C; Bains RK; Itan Y; Bekele E; Bradman N
Pharmacogenet Genomics; 2016 Jun; 26(6):255-70. PubMed ID: 27139836
[TBL] [Abstract][Full Text] [Related]
40. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
